<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Mon, 17 Mar 2025 01:20:31 +0000</lastBuildDate><item><title>From Graz to global — Innophore’s journey with NVIDIA’s BioNeMo</title><link>https://www.drugdiscoverytrends.com/from-graz-to-global-innophores-journey-with-nvidias-bionemo/</link><description>Austrian biotech startup Innophore has gained significant attention after being showcased by NVIDIA CEO Jensen Huang, allowing them to leverage NVIDIA's computational power through their Catalophore platform for AI-driven drug safety screening and binding-site analysis. This collaboration marks a pivotal moment in Innophore's journey as they aim to expand their reach globally.</description><pubDate>Tue, 28 Jan 2025 19:56:15 +0000</pubDate></item><item><title>Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years</title><link>https://www.drugdiscoverytrends.com/lillys-fda-approval-for-omvoh-close-up-nearly-90-of-one-year-responders-maintained-remission-through-two-years/</link><description>The FDA has granted approval for Omvoh (mirikizumab-mrkz), marking it as the first biologic to receive authorization for Crohn's disease in over 15 years, supported by Phase 3 two-year efficacy data. In the pivotal VIVID-1 trial, 53% of patients treated with Omvoh achieved clinical remission after one year, significantly outperforming the 36% observed in the placebo group.</description><pubDate>Fri, 31 Jan 2025 19:00:44 +0000</pubDate></item><item><title>How 3T Biosciences’ platform targets immunologically cold solid tumors</title><link>https://www.drugdiscoverytrends.com/3t-biosciences-targeted-strategy-for-mss-colorectal-cancer/</link><description>3T Biosciences is addressing the therapeutic challenge of immunotherapy resistance in solid tumors, particularly in microsatellite stable colorectal cancer (MSS CRC), where over 90% of cases do not respond to existing checkpoint inhibitors. Their innovative platform aims to enhance treatment effectiveness by targeting immunologically cold solid tumors and improving patient outcomes in oncology.</description><pubDate>Sat, 01 Feb 2025 05:12:51 +0000</pubDate></item><item><title>Complexity’s counterpoint: Understanding protocol optimization</title><link>https://www.drugdiscoverytrends.com/complexitys-counterpoint-understanding-protocol-optimization/</link><description>The clinical research landscape is experiencing a rise in protocol complexity, characterized by an increase in endpoints and procedures across all trial phases and therapeutic areas. This trend reflects the growing sophistication of trial designs, necessitating a focus on protocol optimization to streamline processes.</description><pubDate>Mon, 10 Feb 2025 20:33:52 +0000</pubDate></item><item><title>Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology</title><link>https://www.drugdiscoverytrends.com/flatiron-health-sees-shift-from-what-if-to-what-is-in-real-world-evidence-in-oncology/</link><description>Flatiron Health is witnessing a transformative shift in oncology research, moving from speculation about AI's potential in healthcare to tangible outcomes, as noted by Blythe Adamson, the company's head of outcomes research. This change reflects a growing confidence in AI's capabilities following advancements like ChatGPT, signaling a new era for real-world evidence in cancer care.</description><pubDate>Wed, 12 Feb 2025 03:39:41 +0000</pubDate></item><item><title>Atropos Health CEO Dr. Brigham Hyde on closing healthcare’s evidence gap with AI-driven insight</title><link>https://www.drugdiscoverytrends.com/atropos-health-ceo-dr-brigham-hyde-on-closing-healthcares-evidence-gap-with-ai-driven-insight/</link><description>Atropos Health CEO Dr. Brigham Hyde aims to bridge the "evidence gap" in modern medicine by leveraging AI-driven insights to enhance decision-making in healthcare. His approach seeks to address the challenges posed by inadequate data and guidance from clinical trials.</description><pubDate>Fri, 14 Feb 2025 03:09:10 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>A phase 2b trial of rosnilimab shows promise in treating rheumatoid arthritis (RA) by targeting the PD-1 pathway to reset the immune system, potentially offering a new approach for patients who have not achieved long-term remission with existing therapies. This novel treatment could address the unmet needs of those cycling through traditional options like methotrexate and biologics.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>The challenge of AI inventorship in healthcare</title><link>https://www.drugdiscoverytrends.com/the-challenge-of-ai-inventorship-in-healthcare/</link><description>Generative AI is revolutionizing drug discovery by accelerating the identification of new therapeutics and reducing research and development timelines significantly. As several AI-assisted drugs enter clinical trials, the challenge of patent protection for these innovative therapies raises important questions about AI inventorship in healthcare.</description><pubDate>Fri, 21 Feb 2025 14:15:42 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Avacare Clinical Research Network's new white paper highlights innovative, data-driven strategies to tackle recruitment challenges and boost diversity in vaccine trials, ensuring more efficient and representative study outcomes. Sponsored by Avacare, the resource offers actionable insights for optimizing trial design and participant engagement through cutting-edge approaches.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>COTA Healthcare announces AI milestone in real-world oncology data</title><link>https://www.drugdiscoverytrends.com/cota-healthcare-announces-ai-milestone-in-real-world-oncology-data/</link><description>COTA Healthcare has announced a significant breakthrough in real-world oncology data with the launch of a generative AI platform that streamlines and enhances the curation of cancer data. This advancement heralds a transformative shift in the industry, making the data abstraction process more accurate and profitable.</description><pubDate>Wed, 26 Feb 2025 19:00:13 +0000</pubDate></item><item><title>Successful Scale-Up Of An Upstream Viral Vector Process Using An Adherent Platform</title><link>https://www.fiercebiotech.com/premium/webinar/1368645</link><description>Cytiva's webinar, featuring Brian Gardell, explores scaling challenges in viral vector manufacturing for cell and gene therapies, emphasizing the need for cost-effective, standardized processes to meet clinical demand. The session highlights a case study on successfully scaling a helper-dependent adenovirus (HDAd) production process from bench optimization to commercial readiness using adherent culture platforms.</description><pubDate>Thu, 27 Feb 2025 16:40:10 +0000</pubDate></item><item><title>Finding Patients, Closing Treatment Gaps, and Building Better Messaging through AI and Real-World Data</title><link>https://www.fiercebiotech.com/premium/webinar/1368842</link><description>OM1's upcoming webinar, featuring experts Joseph Zabinski and Kathryn Starzyk, explores how AI-driven digital phenotyping and real-world data can help pharmaceutical teams identify underserved patient populations and align therapies with unmet clinical needs. The session will demonstrate strategies to bridge treatment gaps, refine market messaging, and ensure therapies reach overlooked communities through advanced analytics.</description><pubDate>Thu, 06 Mar 2025 20:09:20 +0000</pubDate></item><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II</title><link>https://www.biospace.com/drug-development/novos-studies-of-glp-1s-for-addiction-limited-to-ongoing-phase-ii</link><description>Novo Nordisk clarified it has no additional clinical trials exploring GLP-1 drugs for addiction beyond a Phase II study testing semaglutide and two other medications, despite recent speculation. The trial, which includes alcohol use disorder as a secondary endpoint, remains the sole focus for potential substance use applications, following a company official’s earlier comments.</description><pubDate>Fri, 07 Mar 2025 14:29:30 +0000</pubDate></item><item><title>At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis</title><link>https://endpts.com/at-300m-kardigan-startup-former-myokardia-team-unveils-its-first-drug-and-it-comes-from-ionis/</link><description>Former MyoKardia executives launched a heart health biotech startup with $300 million in funding, leveraging undisclosed partnerships to secure in-licensed clinical-stage assets for cardiac therapies. The stealth-mode company remains tight-lipped about specific deals but signals a focus on advancing innovative treatments, attracting attention for its seasoned leadership and strategic collaborations.</description><pubDate>Fri, 07 Mar 2025 16:16:52 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>Amgen, Kyowa Kirin’s Rocatinlimab Picks Up Steam With Late-Stage Atopic Dermatitis Win</title><link>https://www.biospace.com/drug-development/amgens-rocatinlimab-picks-up-steam-with-late-stage-atopic-dermatitis-win</link><description>"September 2024 trial results for rocatinlimab, an experimental antibody, drew mixed analyst reactions due to its underwhelming efficacy in treating a targeted condition. The lukewarm data sparked debate about the drug's future potential, with some holding out hope for protocol adjustments while others questioned its market viability."</description><pubDate>Mon, 10 Mar 2025 13:57:34 +0000</pubDate></item><item><title>Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout</title><link>https://www.biospace.com/drug-development/novo-dips-after-cagrisemas-latest-lower-than-expected-weight-loss-readout</link><description>New clinical trial results revealed CagriSema, a weight-loss drug from Novo, achieved 15.7% weight reduction in diabetic patients over 68 weeks but delivered a disappointing 22.7% in non-diabetic patients by December 2024, falling short of the company’s projected 25% efficacy. The underwhelming performance in non-diabetic trials raises questions about the drug’s competitive edge in the crowded obesity treatment market.</description><pubDate>Mon, 10 Mar 2025 14:14:35 +0000</pubDate></item><item><title>Trevi Therapeutics stock soars on Phase 2a chronic cough data</title><link>https://endpts.com/trevi-therapeutics-stock-soars-on-phase-2a-chronic-cough-data/</link><description>Trevi Therapeutics' chronic cough drug demonstrated a 57% reduction in 24-hour cough frequency versus placebo in a Phase 2a trial, outperforming investor expectations and sparking a 40% surge in its stock ($TRVI) at market open. The breakthrough underscores the treatment’s potential and has ignited optimism among investors about the company’s clinical and commercial prospects.</description><pubDate>Mon, 10 Mar 2025 15:51:40 +0000</pubDate></item><item><title>Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash</title><link>https://www.biospace.com/drug-development/mineralys-hypertension-drug-drops-blood-pressure-in-phase-ii-iii-setting-up-market-clash</link><description>Mineralys Therapeutics saw its stock surge over 50% after announcing successful Phase 2 trial results for its hypertension drug, which significantly reduced blood pressure in patients across two clinical studies. The promising data positions the therapy as a potential leader in the $30 billion hypertension market, heightening investor interest in the company’s future regulatory and commercial plans.</description><pubDate>Mon, 10 Mar 2025 16:11:28 +0000</pubDate></item><item><title>Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial</title><link>https://endpts.com/mired-in-low-expectations-novo-braces-for-upcoming-cagrisema-head-to-head-trial/</link><description>Novo Nordisk's weight loss drug CagriSema underperformed in late-stage trials, missing analyst expectations and marking its second high-profile clinical setback. With mounting pressure on the candidate, its success in future trials has become critical for the company’s competitive pipeline.</description><pubDate>Mon, 10 Mar 2025 16:20:49 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug</title><link>https://www.biospace.com/drug-development/pfizer-arvinas-post-mixed-late-stage-breast-cancer-data-for-closely-watched-protac-drug</link><description>Vepdegestrant’s mixed trial results—stalling on broad progression-free survival but showing promise in a niche patient group—sparked a 43% plunge in Arvinas’ stock, with analysts casting doubt on the drug's long-term viability. While no new deals were announced, the setback raises questions about the company’s ability to attract future partnerships or advance the drug’s commercial prospects.</description><pubDate>Tue, 11 Mar 2025 14:08:28 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Telix’s new lead-212 generator could dispel medical isotope scalability hurdles</title><link>https://www.pharmaceutical-technology.com/news/telixs-new-lead-212-generator-could-dispel-medical-isotope-scalability-hurdles/</link><description>Lead-212-based alpha emitters show potential in cancer therapies, but challenges remain in their commercial supply. Efforts to enhance production and distribution are crucial for harnessing these promising treatments.</description><pubDate>Thu, 13 Mar 2025 11:34:09 +0000</pubDate></item><item><title>Montara Therapeutics adds $20M to seed fundraise for neurology pipeline</title><link>https://endpts.com/montara-therapeutics-adds-20m-to-seed-fundraise-for-neurology-pipeline/</link><description>Montara Therapeutics has secured $20 million in expanded seed financing to advance its preclinical CNS drug candidates, aiming to tackle safety concerns that have historically impeded research and development. This funding will help propel their innovative pipeline towards potential breakthroughs in central nervous system treatments.</description><pubDate>Thu, 13 Mar 2025 12:00:29 +0000</pubDate></item><item><title>MoonLake's CEO on its looming mid-year pivotal readout in skin disease</title><link>https://endpts.com/moonlakes-ceo-on-its-looming-mid-year-pivotal-readout-in-skin-disease/</link><description>MoonLake Immunotherapeutics is set to make waves in the biotech sector with anticipated significant clinical readouts for its Phase 3 trials focused on a painful inflammatory skin condition. These results, expected around mid-year, could dramatically impact the company's stock performance and overall market presence.</description><pubDate>Fri, 14 Mar 2025 09:05:36 +0000</pubDate></item><item><title>Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure</title><link>https://endpts.com/lilly-partnered-fauna-bio-plans-40m-series-a-to-get-into-heart-failure/</link><description>Fauna Bio, a biotech company that leverages data on disease resistance from animals like squirrels, is planning to raise a Series A funding round to advance its first program into clinical trials. The company aims to develop innovative drugs based on its unique research approach.</description><pubDate>Fri, 14 Mar 2025 09:39:55 +0000</pubDate></item><item><title>How biosimulation and virtual trials can bust through clinical trial roadblocks</title><link>https://www.drugdiscoverytrends.com/how-biosimulation-and-virtual-trials-can-bust-through-clinical-trial-roadblocks/</link><description>Over 300 million people globally suffer from rare diseases, with about 95% lacking FDA-approved treatments, presenting significant challenges for traditional clinical trials due to small patient populations. However, emerging biosimulation and virtual trial methods offer a promising solution to overcome these obstacles, as highlighted by Oxana Iliach, vice-chair.</description><pubDate>Fri, 14 Mar 2025 15:54:00 +0000</pubDate></item><item><title>AstraZeneca director says AI must be a “thought partner” in drug discovery</title><link>https://www.pharmaceutical-technology.com/news/astrazeneca-director-says-ai-must-be-a-thought-partner-in-drug-discovery/</link><description>AstraZeneca's senior director of oncology data science highlighted the company's innovative use of artificial intelligence in streamlining drug discovery processes at a recent talk. This approach aims to enhance efficiency and effectiveness in developing new oncology therapies.</description><pubDate>Fri, 14 Mar 2025 16:29:00 +0000</pubDate></item><item><title>AbbVie builds the case for ovarian cancer drug Elahere</title><link>https://pharmaphorum.com/news/abbvie-builds-case-ovarian-cancer-drug-elahere</link><description>AbbVie is banking on new survival data to boost the market performance of its rapidly growing ovarian cancer treatment, Elahere. The company aims to leverage this data to enhance patient outcomes and strengthen its position in the oncology market.</description><pubDate>Sun, 16 Mar 2025 19:56:12 +0000</pubDate></item></channel></rss>